In the last trading session, 2.12 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.65. Most recently the company’s share price was $9.19, and it changed around $0.76 or 9.02% from the last close, which brings the market valuation of the company to $440.57M. RDUS currently trades at a discount to its 52-week high of $23.00, offering almost -150.27% off that amount. The share price’s 52-week low was $4.97, which indicates that the current value has risen by an impressive 45.92% since then. We note from Radius Health Inc.’s average daily trading volume that its 3-month average coming to 871.04K.
Radius Health Inc. stock received a consensus recommendation rating of a Hold, based on a mean score of 3.30. If we narrow it down even further, the data shows that 1 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 7 recommended RDUS as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Radius Health Inc. is expected to report earnings per share of $0.05 for the current quarter.
Radius Health Inc. (NASDAQ:RDUS) trade information
Instantly RDUS has showed a green trend with a performance of 9.02% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 9.74 on Tuesday, 06/21/22 increased the stock’s daily price by 5.65%. The company’s shares are currently up 32.80% year-to-date, but still up 34.16% over the last five days. On the other hand, Radius Health Inc. (NASDAQ:RDUS) is 57.36% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $9.00, which translates to bulls needing to decrease their stock price by -2.11% from its current value. Analyst projections state that RDUS is forecast to be at a low of $7.00 and a high of $14.00. In order for the stock price to hit the forecast high, the stock would need to plunge -52.34% from its current level, while the stock would need to crash 23.83% from its current level to reach the projected low.
Radius Health Inc. (RDUS) estimates and forecasts
Radius Health Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 30.17 percent over the past six months and at a 80.54% annual growth rate that is well above the industry average of 11.30%. Moreover, analysts have decided to roll up on their fiscal year 2022 revenue estimates. The rating firms predict that it will gain 114.30% in revenue this quarter, and will report an increase of 85.10% in the next quarter. The year-over-year growth rate is expected to be 5.10%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of $67.21 million in revenue for the current quarter. 5 analysts expect Radius Health Inc. to make $60.99 million in revenue for the quarter ending Sep 2022. Forecasts for the next quarter put sales growth at 7.40%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.90%. Radius Health Inc. earnings are expected to increase by 36.80% in 2022, but the outlook is positive 29.60% per year for the next five years.
Radius Health Inc.’s next quarterly earnings report is expected to be released around February 23 and February 28.
Radius Health Inc. (NASDAQ:RDUS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.85% of Radius Health Inc. shares, and 112.49% of them are in the hands of institutional investors. The stock currently has a share float of 113.46%. Radius Health Inc. stock is held by 200 institutions, with Bellevue Group AG being the largest institutional investor. By Dec 30, 2021, it held 16.33% of the shares, which is about 7.77 million shares worth $53.76 million.
Rubric Capital Management LP, with 14.63% or 6.96 million shares worth $48.16 million as of Dec 30, 2021, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 30, 2022. The former held 3.87 million shares worth $29.31 million, making up 8.13% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.32 million shares worth around $9.12 million, which represents about 2.77% of the total shares outstanding.